Unlocking the promise of cell therapy via the optimized immune cell engager platform
Acepodia is developing potent, off-the-shelf targeted cancer cell therapies that unlock the immune system’s ability to fight both solid tumors and hematological malignancies.
Antibody-Cell Conjugation (ACC), is inherited from Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry which moves click chemistry into living organisms. And she won the Nobel Prize for Chemistry in 2022. ACC technology uses this live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human immune cells. This powerful, new approach to cell therapy development has the potential to dramatically enhance the ability of oNK cells and γδ2 T cells to recognize and engage the tumor by unlocking multiple receptor signaling pathways. This could potentially allow ACC-γδ2 T and oNK therapies to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.
In order to develop the most effective immunotherapies possible, Acepodia equips its ACC technology to both of its proprietary gamma delta2 (γδ2) T cells and off-the-shelf NK (oNK) cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody, new or existing, to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to our already potent and off-the-shelf biologic drug payloads.
PROMISING PIPELINE OF CELL THERAPIES
